COVID-19 disease. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment will received 0.5mg/kg prednisolone in three divided doses up to 30 mg per d
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: COVID-19 patient with Acute Respiratory Distress Syndrome (ARDS) and confirmed by positive PCR test for SARS-CoV-2 or confirmed by abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass opacities), With blood oxygen saturation <93%, Not responding to stamdard COVID-19 treatment after 48-72h
Exclusion criteria
Exclusion criteria: A history of type I diabetes, asthma and lung diseases, malignancies, kidney and heart failure, uncontrolled high blood pressure, positive pro-calcitonin and active infection Taking immunosuppressive drugs and corticosteroids Pregnant or lactating women Prescribing antibiotics due to a bacterial infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiographic features findings. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after treatment with Prednisolone. Method of measurement: Observation.;O2 saturation. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Pulse Oximeter.;Need for an oxygen therapy. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Clinical. | — |
Secondary
| Measure | Time frame |
|---|---|
| CBC laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical.;ESR laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical.;CRP laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical.;Ferritin laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical.;D-Dimer laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical.;Troponin laboratory test. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Para-clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmadreza Jamshidi
Tehran University of Medical Sciences
Outcome results
None listed